资源描述:
《西格列汀联合二甲双胍治疗2型糖尿病的临床效果》由会员上传分享,免费在线阅读,更多相关内容在工程资料-天天文库。
1、[摘要]目的探讨西格列汀联合二甲双脈治疗2型糖尿病(T2DM)的临床效果及安全性。方法收集2010年1月〜2013年6月就诊于岳阳市第二医院的T2DM患者122例。将其分为三组:二甲双孤组(38例,二甲双M0.5g,每天2次)、西格列汀组(42例,西格列汀100mg,每天1次)和联合用药组(42例,二甲双弧联合西格列汀)。12周后观察并比较三组间各项指标的变化。结果治疗后二甲双弧组、西格列汀组与联合用药组体重指数、空腹血糖、餐后2h血糖、糖化血红蛋白(HbAlc)较治疗前均下降(均P<0.05)0与二甲双弧组或西格列
2、汀组单药治疗后比,联合用药组治疗后体重指数、空腹血糖、餐后2h血糖及HbAlc均显著下降(均PV0.05)o结论西格列汀治疗T2DM安全有效,进一步联合二甲双肌治疗,其疗效优于单用二甲双肌或西格列汀。[关键词]DPP-4抑制剂;西格列汀;二甲双孤;2型糖尿病[中图分类号]R587[文献标识码]A[文章编号]1673-7210(2014)05(c)-0054-03ClinicaleffectofSitagliptincombinedwithMetformininthetreatmentofpatientswithtyp
3、e2diabetesZHOUDijunSUNWenliDINGRongSHUANGZhenyuXIEMingLIANGYanfangDepartmentofEndocrinology,theSecondHospitalofYueyangCity,Hu^anProvince,Yueyang414000,China[Abstract]ObjectiveToinvestigatetheefficacyandsafetyofSitagliptincombinedwithMetformininthetreatmentoftyp
4、e2diabeticpatients・Methods122patientswererecruitedfromtheSecondHospitalofYueyangCityfromJanuary2010toJune2013・Allpatientsweredividedintothreegroups:Metformingroup(38patients,Metformin0.5g,bid),Sitagliptingroup(42patients,Sitagliptin100mg,qd)andcombinedtherapygr
5、oup(42patients,MetforminandSitagliptin).Thetestindicatorswererecordedandcomparedamongthethreegroupsafter12weeks・ResultsBodymassindex,fastingblood-glucose,2-hourpostprandialbloodglucoseandHbAlcafteretreatmentintheMetformingroup,Sitagliptingroupandcombinedtherapy
6、groupweresignificantlydecreasedcomparedwiththosebeforetreatment(allP<0.05).ComparedwiththoseinMetformingrouporSitagliptingroup,bodymassindex,fastingblood-glucose,2-hourpostprandialbloodglucoseandHbAlcincombinedtherapygroupweresignificantlydecreased(allP<0.05).C
7、onclusionSitagliptinhasefficacyandsafetyforthetreatmentofT2DM・CombinedSitagliptinwithmefforminaremoreeffectivethanSitagliptinormefforminaloneinthetreatmentofT2DM.[Keywords]DPP-4inhibitor;Sitagliptin;Metformin;Type2diabetes中国已经成为糖尿病的重灾区,新近研究显示中国糖尿病和糖尿病前期的患病率分别为9
8、.7%和15.5%,糖尿病患者已达9300万人[1]。2型糖尿病(T2DM)患者诊断初期,其胰岛B细胞功能已出现明显损害,已有的口服药物和胰岛素治疗均不能逆转胰岛细胞功能的进行性减退,此外,还存在低血糖风险、体重增加、血糖控制不稳定等共性问题。肠促胰素效应的发现和应用使人们看到了新的治疗途径。西格列汀属于一类突破性创新药物一一二肽基肽酶-4(D